Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanHKSE:02268 +1.86%50 OCF Margin % is 36.43% as of Dec. 2025, which is 79% above its 10-year median of 20.33. GuruFocus rates HKSE:02268 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks better than 86.76% on this metric.
The historical rank and industry rank for WuXi XDC Cayman's OCF Margin % or its related term are showing as below:
HKSE:02268'
s OCF Margin % Range Over the Past 10 Years
Min: 15.67 Med: 20.33 Max: 29.99
Current: 24.96
During the past 6 years, the highest OCF Margin % of WuXi XDC Cayman was 29.99%. The lowest was 15.67%. And the median was 20.33%.
HKSE:02268's OCF Margin % is ranked better than 86.76% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 5.885
vs HKSE:02268: 24.96
The historical data trend for WuXi XDC Cayman's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02268 vs TMO, DHR, NTRA: OCF Margin % Comparison
For the Diagnostics & Research subindustry, WuXi XDC Cayman's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's OCF Margin % distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman (HKSE:02268) has a OCF Margin % of 36.43% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on WuXi XDC Cayman and its competitors. This is 79% above median its historical median of 20.33. Over the past decade, WuXi XDC Cayman's OCF Margin % has ranged from 15.67 to 29.99. According to the industry distribution chart, WuXi XDC Cayman ranks #27 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 13.2%.
Is WuXi XDC Cayman's OCF Margin % too high?
WuXi XDC Cayman's current OCF Margin % of 36.43% is 79% above median its 10-year median of 20.33. Over the past 10 years, this metric has ranged from a low of 15.67 to a high of 29.99. The Medical Diagnostics & Research industry median OCF Margin % is 5.89. WuXi XDC Cayman's value of 36.43% is 519% above this industry median. Based on the distribution chart, WuXi XDC Cayman ranks #27 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #27 out of 204 companies for OCF Margin %. This places WuXi XDC Cayman in the top 13% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 5.89. WuXi XDC Cayman's value of 36.43% is 519% above this benchmark. Historically, WuXi XDC Cayman's own OCF Margin % has ranged from 15.67 to 29.99 over the past decade. While the company's 10-year median is 20.33 vs. the industry median of 5.89, WuXi XDC Cayman has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 5.89, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi XDC Cayman's current OCF Margin % of 36.43% is 519% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on WuXi XDC Cayman and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 5.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi XDC Cayman's current OCF Margin % is 36.43%, which is 79% above median its own 10-year median of 20.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (HKSE:02268) has a current OCF Margin % of 36.43%. The current OCF Margin % is 36.43%, which is 79% above median its 10-year median of 20.33 and 519% above the Medical Diagnostics & Research industry median of 5.89. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For WuXi XDC Cayman (HKSE:02268), the current OCF Margin % is 36.43% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for HKSE:02268
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02268 has been successfully added to your 
